Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
Open Access
- 29 December 2017
- journal article
- case report
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 11 (1) , 1-4
Abstract
There have been several reports on dasatinib-induced reversible pulmonary hypertension. This is the first reported case in Latvia; the patient did not discontinue the drug after the first adverse effects in the form of pleural effusions, which we speculate led only to partial reversion of the disease. A 67-year-old white man with chronic myelogenous leukemia was treated with the dual Src and BCR-ABL tyrosine kinase inhibitor dasatinib. After treatment with dasatinib he had multiple pleural effusions which were suspected to be caused by congestive heart failure. Later a transthoracic Doppler echocardiography and right-sided heart catheterization revealed severe pulmonary hypertension with pulmonary vascular resistance of 12 Wood units and mean pulmonary artery pressure of 53 mmHg. Computed tomography ruled out a possible pulmonary embolism; laboratory specific tests for human immunodeficiency virus, rheumatoid factor, and anti-nuclear antibodies were negative, and dasatinib-induced pulmonary arterial hypertension was diagnosed. A follow-up right-sided heart catheterization and 6-minute walk test done a month after the discontinuation of dasatinib showed significant improvement: mean pulmonary artery pressure of 34 mmHg and pulmonary vascular resistance of 4 Wood units. Patients should always be closely monitored when using dasatinib for a prolonged time. Dasatinib-induced pulmonary hypertension may be fully reversible after the therapy is suspended, but the key factors involved are still unclear and need to be further studied.Keywords
This publication has 9 references indexed in Scilit:
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJournal of Clinical Oncology, 2016
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- A review of the European LeukemiaNet recommendations for the management of CMLAnnals of Hematology, 2015
- Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid LeukemiaCancer Research and Treatment, 2014
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Blood, 2014
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood, 2013
- First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinibJournal of Hematology & Oncology, 2010
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Dasatinib in chronic myeloid leukemia: a reviewTherapeutics and Clinical Risk Management, 2009